Automatic System and Method for Tissue Sectioning, Staining, and Scanning
Summary:
The NCI is seeking licensees to develop an automated digital pathology device compatible with high-throughput data analysis.
Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma
Description of Technology:
Neuroblastomas are the most common extracranial solid tumors in pediatric patients, with 700-800 new cases annually in the United States. Metastatic neuroblastomas have a five-year survival rate of 50% and account for 15% of all pediatric cancer deaths. As such, more effective treatments against high-risk neuroblastomas are urgently needed.
Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent
Description of Technology:
Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which bind to the shed portion of MSLN to quickly lose their therapeutic effectiveness over time.
Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein
Description:
The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of RBD and the ACE2 receptor on human cells is the first of the two critical steps for neutralization of the virus.
Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene
Summary:
The NCI seeks parties interested in licensing this mouse model, including the mice, organs, tissues, and other derivatives from mice carrying deletions of the Zbtb7b gene.
T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy
Summary:
The NCI seeks parties interested in research co-development and/or licensing this library of TCRs targeting CDKN2A mutations.
High Efficacy Vaccine and Microbicide Combination For Use Against HIV
Summary:
NCI is seeking research co-development partners and/or licensees to evaluate, further develop or commercialize this high efficacy vaccine and microbicide combination for use against HIV.
Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain
Summary:
Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners to develop therapeutic cell populations arising out of these technologies. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of one or more therapies to treat various oncologies.
T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias
Description of Technology:
CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have limitations such as resistance to treatment and/or side effects. Resistance mechanisms to the current CD22 therapies involve loss or modulation of target antigen on the cell surface.
Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron
Summary:
The NCI seeks research co-development partners and/or licensees to further develop this nanobody as a possible treatment of COVID-19 infections.